MedPath

Exercise Booster Sessions in People With Multiple Sclerosis

Not Applicable
Completed
Conditions
Multiple Sclerosis
Interventions
Combination Product: Systematic aerobic training
Combination Product: Systematic resistance training
Combination Product: Aerobic training booster sessions
Combination Product: Resistance training booster sessions
Registration Number
NCT04913012
Lead Sponsor
University of Aarhus
Brief Summary

This study wants to investigate whether exercise booster sessions applied in the follow-up period after an exercise intervention can increase the sustainability of exercise induced effects in persons with multiple sclerosis.

The study will be a randomized, multi-site, controlled trial. Participants will from the beginning be allocated to either aerobic training group, resistance training group or control group. After a 12 week exercise intervention, the exercise groups will be additionally randomized to receive either exercise booster sessions + standard care or just standard care in the 40 week follow up period.

It is hypothesized that exercise booster sessions can increase the sustainability of exercise induced effects.

Detailed Description

MS is a chronic, autoimmune, and inflammatory disease of the central nervous system, exemplified through marked demyelination and axonal loss. As a result, symptoms such as fatigue, numbness, weakness, depression, walking difficulties and spasticity frequently appear.

Although there is no cure for MS, several disease-modifying therapies are available. These can potentially slow the progression of disabilities and reduce the overall disease burden. This is of great interest from both an individual perspective, where increased disability is associated with a lowered health-related quality of life, and from a societal perspective, where increased disability is associated with larger costs.

Over the past decades exercise has been shown to be safe, tolerable and beneficial in persons with MS (PwMS). Hence, it is known to be an effective way of treating symptoms such as fatigue7, muscle weakness, walking impairments and depression. As with other chronic diseases, exercise for PwMS has been proposed as "medicine". However, in order to benefit from the positive effects of any kind of treatment (i.e. most medical drugs or exercise) one has to adhere to the prescriptions of the treatment (i.e. dose and timing). Despite all the potential benefits of exercise therapy for PwMS, one of the major challenges relate to long-term maintenance of exercise efforts.

An emerging concept that may hold the potential to increase the sustainability of exercise therapy is supervised "exercise booster sessions" (i.e. training sessions provided regularly throughout the follow-up period, to sustain effects of the preceding exercise intervention). These can be placed regularly during the follow-up period, where patients attend a number of supervised high-intensity exercise sessions, hereby trying to boost the effects of the preceding exercise intervention. Furthermore, exercise booster sessions can potentially motivate the patient to keep exercising throughout the follow up period.

However, the optimal way of utilizing this concept is still not fully understood, and has not yet been tried in neurological patients.

Therefore, the main purpose of the present study is to investigate how exercise booster sessions combined with usual care performed over a period of 40 weeks affects the sustainability of effects on functional capacity induced by a 12-week exercise intervention.

It is hypothesized that participants receiving exercise booster sessions + usual care during follow up will have a better functional capacity at follow up, than the participants receiving usual care only.

The study will be a randomized, multi-site, controlled trial. Participants will from the beginning be allocated to either aerobic training group, resistance training group or control group. After a 12 week exercise intervention, the exercise groups will be additionally randomized to receive either exercise booster sessions + standard care or just standard care in the 40 week follow up period.

The 12 week exercise intervention will consist of 2-3 weekly supervised exercise sessions. The training will be planned by exercise physiologists and performed in a progressive manner. To allow handling of a large number of participants, who is also geographically spread, the exercise intervention will be locally anchored, but at the same time supervised by student employees and controlled by internet- and telephonic communication.

Participants allocated to exercise booster sessions will receive two sessions every fifth week during the follow up period.

The power calculation is based on the primary purpose of the study which is to investigate the effect of frequently applied exercise booster sessions. To set the estimated number of participants, a two-sample two-sided power calculation has been conducted. Based on previous studies, a mean difference on functional capacity between the group receiving usual care and the group receiving exercise booster sessions + usual care, regardless of exercise intervention, is expected to be 6% with a standard deviation (SD) of ±10%.

The level of significance was set as 5% and a statistical power of 80%. According to the power calculation each group shall contain 60 participants (expected drop-out rate of 30 % is included).

The results of these studies can have great clinical implications in many ways. If we find that by adding exercise booster sessions in a follow up period, one can maintain, or maybe even improve, functional capacity over a long period, this would be a novel finding making ground for new rehabilitation opportunities

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • A definite diagnosis of MS, according to the McDonald criteria
  • Walking <650m on 6MWT.
  • Exercising ≤ two sessions per week of moderate-to-high intensity during the past six months.
Exclusion Criteria
  • Comprise comorbidities (cardiovascular-, respiratory-, orthopedic- or other neurological diseases.)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Aerobic training booster groupAerobic training booster sessionsWill receive 12 weeks of aerobic training followed by booster sessions + standard care in the 40 follow up period
Aerobic training booster groupSystematic aerobic trainingWill receive 12 weeks of aerobic training followed by booster sessions + standard care in the 40 follow up period
Resistance training booster groupResistance training booster sessionsWill receive 12 weeks of resistance training training followed by booster sessions + standard care in the 40 follow up period
Resistance training booster groupSystematic resistance trainingWill receive 12 weeks of resistance training training followed by booster sessions + standard care in the 40 follow up period
Aerobic training control groupSystematic aerobic trainingWill receive 12 weeks of aerobic training followed by standard care in the 40 follow up period
Resistance training control groupSystematic resistance trainingWill receive 12 weeks of resistance training followed by standard care in the 40 follow up period
Primary Outcome Measures
NameTimeMethod
Change in functional capacity measured as a composite score of the six minute walk test and the 5x sit to stand test (5STS).Baseline,12 weeks and 52 weeks.

The six minute walk test it the distance covered during a six-minute maximal walking test. The 5STS is the time used to stand up from a chair and sit again five times.

Secondary Outcome Measures
NameTimeMethod
Change in functional capacity measured by the Multiple Sclerosis Functional Composite (MSFC)Baseline, 12 weeks and 52 weeks.

Composite score from Timed 25-Feet Walk Test (T25FWT), 9-Hole Peg Test (9HPT), Paced Auditory Serial Addition Test (PASAT)

Change in functional capacity measured by the Six spot step test (SSST)Baseline, 12 weeks and 52 weeks.

SSST is a measure of walking ability, balance and coordination. Measured as the time to complete the six-spot course.

Trial Locations

Locations (1)

Aarhus University

🇩🇰

Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath